Search

Your search keyword '"Llao, J"' showing total 29 results
Start Over Author "Llao, J"
29 results on '"Llao, J"'

3. Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)

Author

Garcia, MJ, Rivero, M, Fernandez-Clotet, A, de Francisco, R, Sicilia, B, Mesonero, F, de Castro, ML, Casanova, MJ, Bertoletti, F, Alonso, FJG, Garcia, AL, Julian, B, Calvet, X, Acosta, MBD, Jara, L, Varela, P, Nunez, A, Ricart, E, Riestra, S, Arias, L, Rodriguez, M, Arranz, L, Pajares, R, Mena, R, Calafat, M, Camo, P, Jimenez, L, Ponferrada, A, Madrigal, RE, Llao, J, Sese, E, Almela, P, Codesido, L, de la Maza, S, Leal, C, Sanchez, E, Marino, JRP, Domenech, E, Chaparro, M, and Gisbert, JP

Published
2022

5. DOP78 Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)

Author

García, M J, primary, Rivero, M, additional, Fernández-Clotet, A, additional, de Francisco, R, additional, Sicilia, B, additional, Mesonero, F, additional, de Castro, M L, additional, Casanova, M J, additional, Bertoletti, F, additional, García Alonso, F J, additional, López García, A, additional, Julián, B, additional, Calvet, X, additional, Barreiro-de Acosta, M, additional, Jara, L, additional, Varela, P, additional, Nuñez, A, additional, Ricart, E, additional, Riestra, S, additional, Arias, L, additional, Rodríguez, M, additional, Arranz, L, additional, Pajares, R, additional, Mena, R, additional, Calafat, M, additional, Camo, P, additional, Jiménez, L, additional, Ponferrada, A, additional, Madrigal, R E, additional, Llao, J, additional, Sesé, E, additional, Almela, P, additional, Codesido, L, additional, de la Maza, S, additional, Leal, C, additional, Sánchez, E, additional, Pineda Mariño, J R, additional, Domènech, E, additional, Chaparro, M, additional, and Gisbert, J P, additional

Published
2022
Full Text
View/download PDF

6. Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry

Author

Chaparro, M, Garre, A, Mesonero, F, Rodriguez, C, Barreiro-de Acosta, M, Martinez-Cadilla, J, Arroyo, MT, Mancenido, N, Sierra-Ausin, M, Vera-Mendoza, I, Casanova, MJ, Nos, P, Gonzalez-Munoza, C, Martinez, T, Bosca-Watts, M, Busquets, D, Calafat, M, Girona, E, Llao, J, Martin-Arranz, MD, Piqueras, M, Ramos, L, Suis, G, Bermejo, F, Carbajo, AY, Casas-Deza, D, Fernandez-Clotet, A, Garcia, MJ, Ginard, D, Gutierrez-Casbas, A, Hernandez-Villalba, L, Lucendo, AJ, Marquez, L, Merino-Ochoa, O, Rancel, FJ, Taxonera, C, Sanroman, AL, Rubio, S, Domenech, E, and Gisbert, JP

Published
2020

7. Low adhesion to latent tuberculosis (TB) screening recommendations in inflammatory bowel disease (IBD) patients: Results of the INFEII registry of GETECCU

Author

Abdo, YZ, de Francisco, R, Rodriguez-Lago, I, Chaparro, M, Gomollon, F, Piqueras, M, Llao, J, Sicilia, B, Domenech, E, Garcia-Bosch, O, de Castro, L, Calvet, X, Morales, V, Rivero, M, Lucendo, AJ, Navarro, P, Marquez, L, Busquets, D, Guardiola, J, Gordillo, J, Iglesias, E, Beltran, B, Sese, E, Ferreiro-Iglesias, R, Francisco, M, Pajares, R, Algaba, A, Vicente, R, Benitez, O, Aceituno, M, Riestra, S, Rodriguez-Pescador, A, Gisbert, JP, Arroyo, MT, Mena, R, Sainz, E, Arias-Garcia, L, Manosa, M, Navarro, M, Sanroman, L, Villoria, A, Delgado-Villena, P, Garcia, MJ, Angueira, T, Minguez, M, Murciano, F, Arajol, C, and Esteve, M

Published
2020

8. Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry

Author

Torres-Rodriguez, P, Canete, F, Calafat, M, Sanchez-Aldehuelo, R, Rivero, M, Iborra, M, Gonzalez-Vivo, M, Vera, I, de Castro, L, Bujanda, L, Barreiro-de Acosta, M, Calvet, X, Benitez, J, Llorente, M, Suris, G, Arias-Garcia, L, David, M, Castano-Garcia, A, Garcia-Alonso, F, Rufo, L, Ferrer, J, Camo, P, Gisbert, J, Huguet, J, Pajares, R, Morales, V, Llao, J, Rodriguez, A, Rodriguez, C, Navarro, M, Gomollon, F, Carrillo-Palau, M, Sese, E, Almela, P, de la Piscina, P, Rodriguez-Lago, I, Papo, M, Vela, M, Manosa, M, Domenech, E, and Eneida-GETECCU Investigators

Published
2020

9. Long-term effectiveness of anti-TNF agents in symptomatic stricturing Crohn's disease

Author

Rodriguez-Lago, I, Del Hoyo, J, Casanova, MJ, Fernandez-Clotet, A, Garcia, MJ, Ferreiro-Iglesias, R, Piqueras, M, Suarez, C, Lopez-Garcia, A, Arroyo, M, Sierra, M, Delgado-Guillena, P, Guerra, I, Merino, O, Arranz, L, Llao, J, Plaza, R, Molina, G, Torres, P, Perez-Galindo, P, Herrera-deGuise, C, Armesto, E, Mesonero, F, Aguirre, U, and Gisbert, JP

Published
2020

11. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

Author

Chaparro, M, Garre, A, Ricart, E, Iglesias-Flores, E, Taxonera, C, Manosa, M, Mendoza, IV, Minguez, M, Arguelles, F, Parga, LD, Arroyo, M, Lopez-Sanroman, A, Tirado, MR, Guardiola, J, Arranz, MDM, Beltran, B, Barrio, J, Riestra, S, Garcia-Planella, E, Calvet, X, Alcain, G, Sicilia, B, Garcia, S, Esteve, M, Marquez, L, Salazar, LIF, Casbas, AG, Piqueras, M, Bermejo, F, Calle, JLP, Hinojosa, J, Perez, AR, Aldeguer, X, Sepulcre, MFG, Bujanda, L, Montiel, PM, Poyatos, RL, Gutierrez, CR, Merino, O, Cabriada, JL, Roncero, O, Cara, PR, Navarro-Llavat, M, Ber, Y, Madrigal, RE, Van Domselaar, M, Barreiro-de Acosta, M, Llao, J, Ramos, L, Riera, J, Villarin, AJL, Gonzalez, ER, Malaves, JMH, Villafranca, CM, Almela, P, Charro, M, de la Piscina, PR, Sese, E, Lacruz, AA, Khorrami, S, Alvarado, VJM, Gil, JL, Martinez, AMT, Villaroya, RP, Acevedo, J, Herola, AG, Villalba, LH, Munoz, E, Duran, MTN, Menacho, M, Lopez, VMN, Retamero, MD, Bernardo, D, Muriel, A, Domenech, E, Gisbert, JP, and ENEIDA Study Grp

Abstract

Background Cohort studies comparing the characteristics of childhood-onset and adulthood-onset inflammatory bowel disease (IBD) in the biologics era are scarce. Aim To compare disease characteristics, the use of immunomodulators and biologic agents and the need for surgery between childhood- and adulthood-onset IBD. Methods Inflammatory bowel disease patients from the ENEIDA registry diagnosed between 2007 and 2017 were included. The childhood-onset cohort comprised patients diagnosed at 16 years. The cumulative incidences of immunosuppressive therapy, biologic therapy and surgery were estimated using Kaplan-Meier curves, compared by the log-rank test. Cox regression analysis was performed to identify potential predictive factors of treatment with immunosuppressants, biologic agents or surgery. Results The adulthood-onset cohort comprised 21 200 patients out of 20 354 (96%) and the childhood-onset cohort 846 (4%). Median follow-up was 54 months in the childhood-onset cohort and 38 months in the adulthood-onset cohort (P < 0.01). Proportions of Crohn's disease, ileocolonic involvement and inflammatory behaviour at diagnosis were higher in the childhood-onset cohort. In the multivariate analysis, after adjusting for sex, type of IBD, extraintestinal manifestations, family history and smoking habit, childhood-onset IBD was associated with higher risk of immunomodulator use (hazard ratio [HR] = 1.2, 95% confidence interval [95% CI] = 1.1-1.2) and higher probability of receiving biologic treatment (HR = 1.2, 95% CI = 1.1-1.3). However, childhood-onset IBD was not associated with higher risk of surgery (HR = 0.9, 95% CI = 0.8-1.2). Conclusions Childhood-onset IBD has differential characteristics and higher risk of treatment with immunomodulators and biologic agents, compared with adulthood-onset IBD. Nevertheless, paediatric IBD is not associated with higher risk of surgery.

Published
2019

12. Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry

Author

Calafat, M, Manosa, M, Panes, J, Nos, P, Iglesias, E, Vera, I, Lopez-Sanroman, A, Guardiola, J, Taxonera, C, Minguez, M, Martin, MD, de Castro, L, Riestra, S, Rivero, M, Garcia-Planella, E, Calvet, X, Garcia-Lopez, S, Andreu, M, Gomollon, F, Barrio, J, Esteve, M, Rodriguez, A, Gisbert, JP, Gutierrez, A, Hinojosa, J, Arguelles, F, Busquets, D, Bujanda, L, Lazaro, J, Sicilia, B, Merino, O, Martinez, P, Bermejo, F, Lorente, R, Barreiro-de-Acosta, M, Rodriguez, C, Fe, M, Piqueras, M, Romero, P, Rodriguez, E, Roncero, O, Llao, J, Alcain, G, Riera, J, Sierra, M, Salazar, LIF, Jair, V, Navarro, M, Montoro, MA, Munoz, C, Lucendo, AJ, Van Domselaar, M, Moraleja, I, Huguet, M, Ramos, L, Ramirez, P, Almeda, P, Pajares, R, Khorrami, S, Madrigal, RE, Sese, E, Trapero, AM, Legido, J, Abad, A, Canete, F, Cabre, E, and Domenech, E

Published
2019

13. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission

Author

Garcia-Planella, E, Manosa, M, Chaparro, M, Beltran, B, Barreiro-de-Acosta, M, Gordillo, J, Ricart, E, Bermejo, F, Garcia-Sanchez, V, Piqueras, M, Llao, J, Gisbert, JP, Cabre, E, Domenech, E, and PRECUCAL Study Grp Investigators

Subjects
relapse, Fecal calprotectin, remission, semi-quantitative, ulcerative colitis
Abstract

Background: Fecal calprotectin (FC) correlates with clinical and endoscopic activity in ulcerative colitis (UC), and it is a good predictor of relapse. However, its use in clinical practice is constrained by the need for the patient to deliver stool samples, and for their handling and processing in the laboratory. The availability of hand held devices might spread the use of FC in clinical practice.Objectives: To evaluate the usefulness of a rapid semi-quantitative test of FC in predicting relapse in patients with UC in remission.Materials and methods: Prospective, multicenter study that included UC patients in clinical remission for 6 months on maintenance treatment with mesalamine. Patients were evaluated clinically and semi-quantitative FC was measured using a monoclonal immunochromatography rapid test at baseline and every three months until relapse or 12 months of follow-up.Results: One hundred and ninety-one patients had at least one determination of FC. At the end of follow-up, 33 patients (17%) experienced clinical relapse. Endoscopic activity at baseline (p=.043) and having had at least one FC>60g/g during the study period (p=.03) were associated with a higher risk of relapse during follow-up. We obtained a total of 636 semi-quantitative FC determinations matched with a three-month follow-up clinical assessment. Having undetectable FC was inversely associated with early relapse (within three months), with a negative predictive value of 98.6% and a sensitivity of 93.9%.Conclusions: Serial, rapid semi-quantitative measurement of FC may be a useful, easy and cheap monitoring tool for patients with UC in remission.

Published
2018

14. Prevalence and risk factors for colorectal adenomas in patients with ulcerative colitis

Author

Gordillo, J, Zabana, Y, Garcia-Planella, E, Manosa, M, Llao, J, Gich, I, Marin, L, Szafranska, J, Sainz, S, Bessa, X, Cabre, E, and Domenech, E

Subjects
colorectal adenoma, metachronous lesion, Ulcerative colitis, risk factors, colorectal cancer
Abstract

Background: Patients with ulcerative colitis (UC) have an increased risk of colorectal cancer. Scarce data regarding the development of adenomas in these patients are available both for normal and colitic mucosa. Objective: The objective of this article is to evaluate the prevalence of adenomatous polyps and associated risk factors in patients with UC. Methods: Patients with UC were identified from the databases of two tertiary referral centers. Medical, endoscopic and histologic reports were reviewed. Results: A total of 403 patients were included (53% male; 33% extensive colitis) and 1065 colonoscopies (median per patient, 2) were recorded and analyzed. Seventy-four adenomas in 47 patients (11.7%) and three cases of colorectal cancer were found during a median follow-up of 6.3 years. The cumulative risk of colorectal adenoma was 4.7%, 16.7%, 23.6% and 34.4% at 10, 20, 30 and 40 years from UC diagnosis, respectively. The cumulative risk of developing metachronous colorectal adenoma was 66.7%, 87.9%, and 90.9% at 5, 10, and 15 years from first adenoma detection. Older age at UC diagnosis and longer disease duration were independent risk factors for colorectal adenoma development. Conclusions: The prevalence of colorectal adenomas among UC patients seems to be higher than previously reported, although lower than in the background population.

Published
2018

17. Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989-2013): a multicenter nationwide study

Author

Ordas, I, Domenech, E, Aguas, M, Fernandez-Banares, F, Garcia, S, Penalva, M, Munoz, C, Garcia-Sanchez, V, Llao, J, Jimenez, CE, Merino, O, Gomollon, F, Piqueras, M, Vera, M, Marquez, L, De Castro, M, Gutierrez, A, Cabriada, JL, Alcaide, N, Calvet, X, Montoro, MA, Arias, L, Panes, J, and Esteve, M

Published
2017

18. P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU

Author

Chaparro, M, primary, Garre, A, additional, Ricart, E, additional, García-Sánchez, V, additional, Taxonera, C, additional, Mañosa, M, additional, Vera Mendoza, I, additional, Mínguez, M, additional, Argüelles, F, additional, De Castro Parga, L, additional, Arroyo, M, additional, López-San Román, A, additional, Rivero Tirado, M, additional, Guardiola, J, additional, Martín Arranz, M D, additional, Beltrán, B, additional, Barrio, J, additional, Riestra, S, additional, García-Planella, E, additional, Calvet, X, additional, Alcaín, G, additional, Sicilia, B, additional, García, S, additional, Esteve, M, additional, Márquez, L, additional, Fernández Salazar, L, additional, Gutiérrez Casbas, A, additional, Piqueras, M, additional, Guerra, I, additional, Pérez Calle, J L, additional, Hinojosa, J, additional, Rodríguez, A, additional, Aldeguer, X, additional, García-Sepulcre, M, additional, Bujanda, L, additional, Martínez Montiel, P, additional, Llorente Poyatos, R, additional, Rodríguez Gutiérrez, C, additional, Merino, O, additional, Cabriada, J L, additional, Roncero, O, additional, Romero Cara, P, additional, Navarro-Llavat, M, additional, Ber, Y, additional, Madrigal, R, additional, Van Domselaar, M, additional, Barreiro-de Acosta, M, additional, Llao, J, additional, Ramos, L, additional, Riera, J, additional, Lucendo Villarín, A J, additional, Rodríguez González, E, additional, Huguet Malavés, J M, additional, Muñoz Villafranca, C, additional, Almela, P, additional, Charro, M, additional, Ramírez de la Piscina, P, additional, Sese, E, additional, Abad Lacruz, Á, additional, Khorrami, S, additional, Morales Alvarado, V J, additional, Legido Gil, J, additional, Trapero Martínez, A M, additional, Pajares, R, additional, Acevedo, J, additional, García Herola, A, additional, Hernández Villalba, L, additional, Muñoz, E, additional, Novella Durán, M T, additional, Menacho, M, additional, Navas López, V M, additional, Retamero, M D, additional, Domènech, E, additional, and Gisbert, J P, additional

Published
2018
Full Text
View/download PDF

19. DOP051 Usefulness of a faecal calprotectin rapid semiquantitative test in predicting relapse in patients with ulcerative colitis in remission

Author

Garcia-Planella, E., primary, Manyosa, M., additional, Chaparro, M., additional, Barreiro-de-Acosta, M., additional, Beltrán, B., additional, Ricart, E., additional, García-Sánchez, V., additional, Esteve, M., additional, Piqueras, M., additional, Bermejo, F., additional, López-Sanromán, A., additional, Taxonera, C., additional, Llao, J., additional, Gisbert, J.P., additional, Cabré, E., additional, and Domènech, E., additional

Published
2014
Full Text
View/download PDF

24. The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn's disease but not in ulcerative colitis. A nationwide study from the Eneida registry

Author

Guasch, M., Clos, A., Ordas, I., Garcia-Sanchez, V., Gisbert, J. P., Taxonera, C., Vera, I., Minguez, M., Guardiola, J., Lopez-Sanroman, A., Rivero-Tirado, M., Nos, P., Gomollon, F., Carbajo, A. Y., Francisco, R., Martin-Arranz, M. D., Garcia-Planella, E., Garcia-Lopez, S., Castro, L., Calvet, X., Camargo, R., Esteve, M., Sicilia, B., Andreu, M., Macho, A., Piqueras, M., Bermejo, F., Gutierrez, A., Busquets, D., Martinez-Montiel, P., Hinojosa, J., Perez-Calle, J. L., Luis Bujanda, Rodriguez-Perez, A., Lorente, R., Jimenez, N., Navarro-Llavat, M., Cabriada, J. L., Camo, P., Domselaar, M., Rodriguez-Gonzalez, E., Rodriguez-Gutierrez, C., Huguet, J. M., Lucendo, A. J., Arguelles, F., Almela, P., Merino, O., Calafat, M., Ogueta, M., Charro, M., Llao, J., Munoz, C., Ramos, L., Abad, A., Roncero, O., Barreiro-De-Acosta, M., Sese, E., Manosa, M., and Domenech, E.

25. The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case-control study of the ENEIDA registry

Author

Calafat, M., Manosa, M., Canete, F., Panes, J., Garcia Sanchez, V., Calvo, M., Rodriguez-Moranta, F., Taxonera, C., Nos, P., Lopez Sanroman, A., Martin Arranz, M. D., Minguez, M., Gisbert, J. P., Garcia-Lopez, S., Francisco, R., Gomollon, F., Calvet, X., Garcia-Planella, E., Rivero, M., Martinez-Cadilla, J., Arguelles, F., Arias Garcia, L., Cimavilla, M., Zabana, Y., Marquez, L., Gutierrez, A., Alcain, G., Martinez Montiel, P., Lazaro, J., Busquets, D., Garcia Sepulcre, M. F., Verdejo, C., Bermejo, F., Mora, M., Monfort, D., Romero, P., Velayos, B., Rodriguez, C., Rodriguez, A., Merino, O., Rodriguez-Pescador, A., Luis Bujanda, Ber, Y., Vela, M., Roncero, O., Huguet, J. M., Garcia-Bosch, O., Barreiro-De-Acosta, M., Madrigal, R. E., Ramos, L., Domselaar, M., Almela, P., Llao, J., Lucendo, A. J., Munoz Vilafranca, C., Abad, A., Charro, M., Legido, J., Riera, J., Khorrami, S., Sese, E., Trapero, A. M., and Domenech, E.

26. Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU

Author

Chaparro, M., Garre, A., Ricart, E., Garcia-Sanchez, V., Taxonera, C., Manosa, M., Vera Mendoza, I., Minguez, M., Arguelles, F., Castro Parga, L., Arroyo, M., Lopez-San Roman, A., Rivero Tirado, M., Guardiola, J., Martin Arranz, M. D., Beltran, B., Barrio, J., Riestra, S., Garcia-Planella, E., Calvet, X., Alcain, G., Sicilia, B., Garcia, S., Esteve, M., Marquez, L., Fernandez Salazar, L., Gutierrez Casbas, A., Piqueras, M., Guerra, I., Perez Calle, J. L., Hinojosa, J., Rodriguez, A., Aldeguer, X., Garcia-Sepulcre, M., Bujanda, L., Martinez Montiel, P., Llorente Poyatos, R., Rodriguez Gutierrez, C., Merino, O., Cabriada, J. L., Octavio Roncero, Romero Cara, P., Navarro-Llavat, M., Ber, Y., Madrigal, R., Domselaar, M., Barreiro-De Acosta, M., Llao, J., Ramos, L., Riera, J., Lucendo Villarin, A. J., Rodriguez Gonzalez, E., Huguet Malaves, J. M., Munoz Villafranca, C., Almela, P., Charro, M., Ramirez La Piscina, P., Sese, E., Abad Lacruz, A., Khorrami, S., Morales Alvarado, V. J., Legido Gil, J., Trapero Martinez, A. M., Pajares, R., Acevedo, J., Garcia Herola, A., Hernandez Villalba, L., Munoz, E., Novella Duran, M. T., Menacho, M., Navas Lopez, V. M., Retamero, M. D., Domenech, E., and Gisbert, J. P.

27. Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry

Author

Torres-Rodriguez, P., Canete, F., Calafat, M., Sanchez-Aldehuelo, R., Rivero, M., Iborra, M., Gonzalez-Vivo, M., Vera, I., Castro, L., Luis Bujanda, Barreiro-De Acosta, M., Calvet, X., Benitez, J. M., Llorente, M., Suris, G., Arias-Garcia, L., David, M., Castano-Garcia, A., Garcia-Alonso, F. J., Rufo, L., Ferrer, J. A., Camo, P., Gisbert, J. P., Huguet, J. M., Pajares, R., Morales, V., Llao, J., Rodriguez, A., Rodriguez, C., Navarro, M., Gomollon, F., Carrillo-Palau, M., Sese, E., Almela, P., Ramirez La Piscina, P., Rodriguez-Lago, I., Papo, M., Vela, M., Manosa, M., and Domenech, E.

28. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.

Author

Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, and Gisbert JP

Subjects
Adalimumab blood, Adalimumab pharmacokinetics, Adult, Anti-Inflammatory Agents blood, Anti-Inflammatory Agents pharmacokinetics, Biological Products blood, Biological Products pharmacokinetics, Colitis, Ulcerative blood, Colitis, Ulcerative diagnosis, Colitis, Ulcerative immunology, Crohn Disease blood, Crohn Disease diagnosis, Crohn Disease immunology, Drug Monitoring methods, Endoscopy, Gastrointestinal, Enzyme-Linked Immunosorbent Assay, Female, Humans, Infliximab blood, Infliximab pharmacokinetics, Intestinal Mucosa immunology, Intestinal Mucosa pathology, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Spain, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha immunology, Adalimumab therapeutic use, Anti-Inflammatory Agents therapeutic use, Biological Products therapeutic use, Colitis, Ulcerative drug therapy, Crohn Disease drug therapy, Infliximab therapeutic use, Intestinal Mucosa drug effects, Tumor Necrosis Factor-alpha antagonists & inhibitors, Wound Healing drug effects
Abstract

Objectives: (a) To evaluate the diagnostic accuracy of anti-TNF trough levels to predict mucosal healing in inflammatory bowel disease (IBD); (b) to determine the best cut-off point to predict mucosal healing in IBD patients treated with anti-TNF., Methods: This is a multicenter, prospective study. IBD patients under anti-TNF treatment for at least 6 months that had to undergo an endoscopy were included. Mucosal healing was defined as: Simple endoscopic score for Crohn's Disease < 3 for Crohn's disease (CD), Rutgeerts score < i2 for CD in postoperative setting, or Mayo endoscopic score ≤ 1 for ulcerative colitis (UC). Anti-TNF concentrations were measured using SMART ELISAs at trough., Results: A total of 182 patients were included. Anti-TNF trough levels were significantly higher among patients that had mucosal healing than among those who did not. The area under the curve of infliximab for mucosal healing was 0.63 (best cutoff value 3.4 μg/mL), and for adalimumab 0.60 (best cutoff value 7.2 μg/mL). In the multivariate analysis, having anti-TNF drug levels above the cutoff values [odds ratio (OR) 3.1]) and having UC instead of CD (OR 4) were associated with a higher probability of having mucosal healing. Additionally, the need for an escalated dosage (OR 0.2) and current smoking habit (OR 0.2) were also associated with a lower probability of mucosal healing., Conclusions: There was an association between anti-TNF trough levels and mucosal healing in IBD patients; however, the accuracy of the determination of infliximab and adalimumab concentrations able to predict mucosal healing was suboptimal.

Published
2019
Full Text
View/download PDF

29. [Usefulness of octreotride in preventing non-variceal gastroinetestinal bleeding in liver cirrhosis: A report of two cases].

Author

Sort P, Isava A, Porta F, Llao J, Puig I, and Vida F

Subjects
Angiodysplasia complications, Angiodysplasia diagnostic imaging, Blood Transfusion, Fatal Outcome, Female, Gastrointestinal Hemorrhage diagnostic imaging, Gastrointestinal Hemorrhage etiology, Gastrointestinal Hemorrhage therapy, Gastroscopy, Hepatitis C, Chronic complications, Humans, Hypertension, Portal etiology, Jejunal Diseases complications, Jejunal Diseases diagnostic imaging, Liver Circulation drug effects, Liver Cirrhosis physiopathology, Liver Cirrhosis, Alcoholic complications, Liver Cirrhosis, Alcoholic physiopathology, Liver Failure etiology, Middle Aged, Octreotide pharmacology, Gastrointestinal Hemorrhage prevention & control, Hypertension, Portal drug therapy, Liver Cirrhosis complications, Octreotide therapeutic use
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results